Pharming Group (NASDAQ:PHAR) Releases Earnings Results, Misses Expectations By $0.08 EPS

Pharming Group (NASDAQ:PHAR) released its quarterly earnings data on Thursday. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.08), FiscalAI reports. Pharming Group had a return on equity of 1.12% and a net margin of 0.71%.The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million.

Here are the key takeaways from Pharming Group’s conference call:

• Pharming delivered a strong 2025: total revenues of €376.1M (+27% YoY), Q4 revenue +15%, adjusted operating profit of €36.4M (vs a loss in 2024), operating cash flow of €54.7M, and year-end cash of €181.1M.
• The company reaffirmed 2026 guidance of €405M–€425M revenue (8–13% growth) and operating expenses of €330M–€335M, with >€60M incremental R&D investment while emphasizing continued financial discipline.
• Near‑term pipeline catalysts could be material: enrollment for leniolisib Phase 2 trials is complete with top‑line data expected in H2 2026, and napazimone pivotal enrollment should finish in 2026 with a readout by end‑2027.
• Regulatory uncertainty for Joenja after an FDA complete response letter for the pediatric 4–11 label; a Type A meeting is scheduled end‑March to define resubmission needs, though CHMP and PMDA decisions in EU/Japan are imminent.
• RUCONEST remains resilient in high‑attack HAE patients but faces competitive pressure from new therapies, and management expects a Q1 2026 US RUCONEST revenue headwind of ~7–9% due to inventory normalization.

Pharming Group Stock Performance

Shares of PHAR traded down $0.63 during mid-day trading on Friday, reaching $14.51. 35,943 shares of the company’s stock traded hands, compared to its average volume of 19,061. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The business’s 50-day moving average price is $17.21 and its 200-day moving average price is $16.06. The stock has a market capitalization of $1.02 billion, a P/E ratio of 1,451.00 and a beta of 0.04. Pharming Group has a 12 month low of $7.50 and a 12 month high of $21.34.

Analysts Set New Price Targets

Several research firms have recently commented on PHAR. HC Wainwright set a $37.00 target price on Pharming Group and gave the company a “buy” rating in a report on Thursday. Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Finally, Oppenheimer reiterated an “outperform” rating and issued a $41.00 target price (down from $42.00) on shares of Pharming Group in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Institutional Trading of Pharming Group

Several large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares in the last quarter. Millennium Management LLC bought a new position in shares of Pharming Group during the 4th quarter valued at about $360,000. SmartHarvest Portfolios LLC bought a new stake in shares of Pharming Group in the 4th quarter worth approximately $224,000. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group in the 2nd quarter worth approximately $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group News Roundup

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.